循环游离核酸在肝细胞肝癌临床诊治中的应用进展  

Clinical application progress of circulating free nucleic acid in the diagnosis and treatment of hepatocellular carcinoma

作　　者：明心亮 刘雪芳 朱满[1] 涂建成[1] MING Xinliang;LIU Xuefang;ZHU Man;TU Jiancheng(Department of Clinical Laboratory, Center for Gene Diagnosis,Zhongnan Hospital of Wuhan University,Wuhan 430071,Hubei,China)

机构地区：[1]武汉大学中南医院检验科检验系基因诊断中心

出　　处：《检验医学》2019年第7期667-671,共5页Laboratory Medicine

基　　金：国家重点基础研究发展计划（973计划）资助项目（2012CB720605）;武汉大学中南医院科技创新培育基金资助项目（ZNPY2016046)

摘　　要：肝细胞肝癌(HCC)是在慢性肝病或肝硬化的基础上逐渐演变形成,是一个多因素、多步骤的发展、恶化过程。由于早期诊断率低,大多数HCC患者在初诊时已处于中晚期或发生肝外转移,常预后不良。随着基因组学研究及其在临床应用中的进展,循环游离核酸(cfNA)等一系列新型标志物相继被发现。cfNA在HCC患者的早期诊断、疗效监测、预后评价及个体化治疗等方面均显示出较好的临床应用前景。文章着重介绍了循环肿瘤DNA(ctDNA)、微小RNA(miRNA)、长链非编码RNA(lncRNA)及环状RNA(circRNA)这4种cfNA在HCC诊治中的应用进展。Hepatocellular carcinoma(HCC)is gradually formed on the basis of chronic liver disease or cirrhosis by a multi-factor and multi-step process of tumor progression.Due to the low determination rate in early diagnosis,the majority of patients with HCC are determined at the middle and advanced stages or accompanied by extrahepatic metastasis with poor prognosis.Recent advances in genomics and its clinical application have discovered a series of novel markers,such as circulating free nucleic acid(cfNA),supported by research data,to be considered having a good clinical application prospect for clinical early diagnosis,the monitoring of therapeutic efficacy,prognosis evaluation and individualized treatment of patients with HCC.This review focuses on the clinical application of circulating tumor DNA(ctDNA),microRNA(miRNA),long non-coding RNA(lncRNA)and circular RNA(circRNA)in the diagnosis and treatment of HCC.

关 键 词：循环游离核酸 肝细胞癌 循环肿瘤DNA 微小RNA 长链非编码RNA 环状RNA 

分 类 号：R446.1[医药卫生—诊断学]